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Introduction
A ﬁxed combination of indomethacin, prochlorpera-
zine and caffeine (hereinafter Indoprocaf) is the most
commonly used drug in Italy for the acute treatment
of migraine and tension-type headache since more
than 30 years. Indomethacin is a non-steroidal anti-
inﬂammatory drug (NSAID), structurally related to
serotonin and endowed with central analgesic and
cranial vasoconstrictor properties (1,2). Indomethacin
was described to block nitric oxide-induced dilation
of dural meningeal vessels (3). In the rat, indometha-
cin administration markedly reduces nitroglycerin-
induced Fos expression in several areas of pain con-
trol system, including nucleus trigeminalis caudalis
(4). Moreover, several evidences indicate a central
analgesic activity of this substance in both human
and experimental studies (5,6). The efﬁcacy of indo-
methacin in abolishing peripheral and central sensiti-
sation in animal models was recently published (7,8).
Indomethacin is the treatment of choice for chronic
paroxysmal hemicrania and hemicrania continua (9)
and showed to be effective in the acute treatment of
migraine and in different types of primary headache
(10–12). Prochlorperazine is a phenothiazine anti-
emetic, endowed with central cholinergic analgesic
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Aims and methods: In this double-blind, double-dummy, randomised, parallel
group, multicentre study, the efﬁcacy of dosing and re-dosing of a ﬁxed combina-
tion of indomethacin, prochlorperazine and caffeine (Indoprocaf) was compared
with encapsulated sumatriptan in the acute treatment of two migraine attacks.
Additionally, in the group taking Indoprocaf, two different oral formulations were
tested: effervescent tablets and encapsulated coated tablets. Results: Of 297
patients randomised (150 assigned to Indoprocaf and 147 to sumatriptan), 281
were included in the intention-to-treat efﬁcacy analysis. The initial dosing of Indo-
procaf and sumatriptan was similarly effective with pain-free rates higher than
30% (95% CI of odds-ratio: 0.57–1.28) and headache relief rates of about 60%
(95% CI of odds-ratio: 0.82–1.84) with both the drugs. The efﬁcacy of re-dosing
of Indoprocaf as rescue medication was more effective than that of sumatriptan
with pain-free values of 47% vs. 27% in the total attacks with a statistically signi-
ﬁcant difference in the ﬁrst migraine attack in favour of Indoprocaf. The efﬁcacy of
re-dosing to treat a recurrence/relapse was very high without differences between
the drugs (pain-free: 60% with Indoprocaf and 50% with sumatriptan in the total
attacks). Indoprocaf and sumatriptan were well-tolerated. Conclusion: The study
demonstrated that the efﬁcacy of the initial dosing of Indoprocaf was not higher
than that of sumatriptan, but that the strategy to use the lowest effective dose as
soon as the headache occurred, followed by a second dose if the headache has
not relieved or to treat a relapse, was very effective, especially with Indoprocaf.
What’s new
Indoprocaf and sumatriptan are the most used
drugs for the treatment of migraine in Italy and
comparison studies between the oral forms of the
two drugs had never been carried out before. In
addition, the results of the study showed that the
strategy to use the lowest effective dose as soon
as the headache occurred, followed by a second
dose if the headache had not relieved or to treat a
relapse, was very effective.
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lorperazine is considered as adjunct ﬁrst-line therapy
for migraine attacks in emergency departments or
ofﬁces, while rectal prochlorperazine is suggested to
be used as associated treatment for migraine attacks
with nausea and vomiting (14). Prochlorperazine has
proved to be clinically effective in the acute treatment
of migraine, also as monotherapy at an oral dosage of
3 mg (15). Caffeine is a methylxanthine used in sev-
eral analgesic preparations because of its central cho-
linergic analgesic properties (16). The analysis of 30
clinical studies involving more than 10,000 patients
showed that, if caffeine is combined with an anal-
gesic, the dose of the analgesic required to obtain the
same pain relief is reduced by 40% (17). A review of
the beneﬁt-risk of caffeine as an analgesic adjuvant
concluded that adding caffeine to analgesics increases
the number of patients who become free of headache
(rate ratio, 1.36; CI, 1.17–1.58) (18).
The pharmacological and clinical proﬁle of the ﬁxed
combination of indomethacin, prochlorperazine and
caffeine (Indoprocaf) has recently been studied. The
three active ingredients of Indoprocaf reverted hyperal-
gesia in in vivo models of migraine at doses 10 times
lower than the corresponding analgesic ones (19). In
these models Indoprocaf showed a signiﬁcantly higher
efﬁcacy compared to the three single active principles
(19). Indoprocaf, but not sumatriptan, was able to abol-
ish the peripheral sensitisation induced by kainic acid
and the central sensitisation induced by N–methyl–
D–aspartate (NMDA), in in vivo models of hyperalgesia
(7). This study suggested that, while triptans seem to be
able to abort migraine attacks only if given before
the establishment of cutaneous allodynia and central
sensitisation (20), Indoprocaf should be able to abort
migraine attacks independently from the time of
administration, being able to abolish an already estab-
lished peripheral and central sensitisation (7).
From a clinical point of view, in a multicentre,
randomised, cross-over clinical trial, Indoprocaf sup-
positories showed to be signiﬁcantly more effective
than sumatriptan 25 mg suppositories in the acute
treatment of migraine attacks with a good tolerability
proﬁle (21). In particular, the study showed that
more attacks were pain-free at 2 h postdose (primary
end-point) on Indoprocaf than on sumatriptan (49%
vs. 34%; p < 0.01). The superiority of Indoprocaf to
sumatriptan in this trial was also conﬁrmed by other
important secondary end-points, as time to pain-free,
alleviation of nausea, sustained pain-free and consis-
tency across and within patients. In a double-blind,
multicentre, randomised, parallel group study, Indo-
procaf, compared with nimesulide, showed to be very
effective and well tolerated in the treatment of epi-
sodic tension-type headache (22).
Sumatriptan, an effective drug for the acute treat-
ment of migraine with and without aura and cluster
headache, is the ﬁrst of the selective 5-HT1B/1D agon-
ists (known as triptans) being discovered, and is
widely considered to be the gold standard in
migraine therapy (23). Indoprocaf and sumatriptan
are the most used drugs for the treatment of
migraine in Italy and comparison studies between
the oral forms of the two drugs have never been car-
ried out. This study, performed according to the sec-
ond edition of the Guidelines for Controlled Trials
of Drugs in Migraine (24), was designed to compare
the efﬁcacy and safety of Indoprocaf effervescent (a
recently developed formulation of Indoprocaf) and
encapsulated coated tablets with encapsulated suma-
triptan 50-mg tablets in the acute treatment of
migraine, using the percentage of pain-free attacks at
2 h after dosing in two migraine attacks in total, as
primary efﬁcacy end-point.
Methods
Patients
In this multicentre study, conducted between Decem-
ber 2002 and June 2004, male or female outpatients
(18–65 years) who met International Headache Soci-
ety (IHS) criteria for migraine with or without aura
(25) were enrolled by specialist physicians of Head-
ache Centres throughout Italy. Patients were eligible
for inclusion if they had a history of migraine of at
least 1 year duration, an age at onset of migraine
< 50 years and had experienced from one to six
attacks per month during the month of screening. At
least moderate headache severity most of the times
and periods between attacks free from headache were
also required. Patients were excluded if they used
drugs for migraine prophylaxis or ergot derivatives
during the month of screening, or if they had a his-
tory or current evidence of drugs (analgesics, ergot
derivatives, opiates or major tranquillisers) or alcohol
abuse according to IHS criteria (25). Other exclusion
criteria were serious illness (including psychiatric dis-
eases) or contraindications to Indoprocaf or to suma-
triptan, and pregnancy or lactation. Patients were also
excluded if they were known to be non-responders to
Indoprocaf or to sumatriptan. Moreover, at baseline
patients should have a normal 12-lead electrocardio-
gram (ECG), no clinically abnormal laboratory tests
including haematology and blood chemistry and a
negative pregnancy test.
The protocol and informed consent form were
approved by independent Ethics Committee at each
clinical centre. A description of the study risks and
beneﬁts was provided to all participants, who gave
written informed consent prior to entry in the study.
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Conference on Harmonisation (ICH) Good Clinical
Practices, to the Guidelines for Controlled Trials of
Drugs in Migraine (24) and to the Note for Guid-
ance on Clinical Investigation of Medicinal Products
for the Treatment of Migraine (26).
Study design and treatments
This study was designed as a double-blind, double-
dummy, randomised, parallel group, multicentre
trial. After 4 weeks of screening, patients were rand-
omised to Indoprocaf-effervescent tablets or Indo-
procaf-coated tablets or sumatriptan 50 mg tablets,
for the treatment of two consecutive migraine attacks
of moderate or severe intensity, separated by at least
48 h. The randomisation was 1:1:2(Indoprocaf-
effervescent tablets:Indoprocaf-coated tablets:suma-
triptan 50 mg tablets) with a blocked randomisation
by centre. The randomisation list was provided from
a computer-generated code list. Patients were sup-
plied with two doses of study medication for each of
two attacks to be treated. The ﬁrst dose had to be
taken as soon as possible when the headache of mod-
erate severity occurred. The second dose had to be
taken either as rescue medication, when the severity
of headache was still moderate (score 2) or severe
(score 3) at 2 h after dosing, or to treat the relapse
of headache, that is if the severity of headache was 0
(no headache) or 1 (mild headache) at 2 h and the
headache returned within 48 h of initial dosing. In
the Indoprocaf-effervescent tablets group, each dose
of study medication consisted of one effervescent
tablet containing indomethacin 25 mg, prochlorpera-
zine 2 mg and caffeine 75 mg and one placebo cap-
sule; in the Indoprocaf-coated tablets group, each
dose of study medication consisted of one encapsula-
ted tablet containing indomethacin 25 mg, prochlor-
perazine 2 mg and caffeine 75 mg and one placebo
effervescent tablet; in the sumatriptan 50 mg tablets
group, each dose of study medication consisted of
one encapsulated tablet containing sumatriptan
50 mg and one placebo effervescent tablet.
Patients should not take any other drug during
the ﬁrst 2 h after initial dosing. For the patients who
took a second dose of study medication, the use of
any other drug to treat the headache was allowed
only 2 h after the intake of the second dose of study
medication. Ergot derivatives and opiates could not
be used as a rescue medication. During the migraine
attack, patients were not permitted to take coffee or
beverages containing caffeine. Patients were sched-
uled to be seen after the treatment of two attacks
and not later than 8 weeks after the randomisation.
During this period ergot derivatives and migraine
prophylactic drugs were not allowed.
At baseline visit, the investigators completed the
MIDAS (Migraine Disability Assessment) question-
naire (27). During the screening and the study
periods patients were given a diary card. During
migraine attack, patients rated their headache sever-
ity in the diary using a four-grade scale (0, no head-
ache; 1, mild headache, allowing normal activities;
2, moderate headache, disturbing normal activities;
3, severe headache, disabling activities, requiring bed-
rest) just before the drug intake and at 0.5, 1, 1.5, 2,
3, 4 and 5 h after ﬁrst dosing. At the same time-
points, patients recorded the presence of associated
symptoms (nausea, vomiting, photophobia, phono-
phobia and osmophobia). Patients also reported if
they used the second dose as rescue medication or to
treat the relapse of headache within 48 h and the
severity of headache 0.5, 1, 1.5 and 2 h after the
second dose intake.
At the ﬁnal visit, unused tablets and capsules and
empty boxes were returned and counted to assess
adherence.
End-points
Pain-free, that is the percentage of attacks with no
headache (0 on the severity of headache scale) at 2 h
after dosing without use of rescue medication, in
two migraine attacks in total was the primary end-
point to compare Indoprocaf tablets and sumatriptan
50 mg tablets.
Secondary efﬁcacy parameters were:
• Pain-free in the ﬁrst and in the second migraine
attack analysed separately;
• Headache relief, that is the percentage of attacks
with mild or no headache (the severity of head-
ache scale to 1 or 0) at 2 h, without use of rescue
medication, in the ﬁrst, in the second and in the
total two migraine attacks;
• Cumulative pain-free, that is the cumulative per-
centage of attacks pain-free at the different obser-
vation times without use of rescue medication;
• Intra-individual consistency, that is the percentage
of patients pain-free (or headache relieved) at 2 h
in two of two migraine attacks;
• Associated symptoms (nausea, vomiting, photo-
phobia, phonophobia and osmophobia), that is
the percentage of attacks with each associated
symptom at 2 h;
• Percentage of attacks free of any associated symp-
toms at 2 h;
• Rescue medication, that is the percentage of
attacks that needed the second dose of study drug
as rescue medication between 2 and 48 h of initial
dosing;
• Second dose efﬁcacy as rescue medication, that is
the percentage of attacks with pain-free (or head-
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the study drug as rescue medication;
• Total pain-free rate, that is the total percentage of
attacks pain-free at 5 h without use of rescue
medication, and 2 h after the second dose of study
drug as rescue medication;
• Recurrence, that is the percentage of attacks with
headache relief at 2 h and worsening of headache
within 24 h of initial dosing;
• Sustained response, that is the percentage of
attacks with headache relief at 2 h, no use of res-
cue medication and no recurrence within 24 h;
• Relapse, that is the percentage of attacks with
pain-free at 2 h and worsening of headache within
48 h of initial dosing;
• Sustained pain-free, that is the percentage of
attacks with pain-free at 2 h, no use of rescue
medication and no relapse within 48 h;
• Use of second dose to treat a recurrence or a
relapse, that is the percentage of attacks that nee-
ded the second dose of study drug to treat a recur-
rence or a relapse;
• Second dose efﬁcacy to treat a recurrence or a
relapse, that is the percentage of recurrences or
relapses with pain-free (or headache relief) 2 h
after the use of a second dose of the study drug.
As subanalysis, a comparison between Indoprocaf-
coated and -effervescent tablets was performed on
the following parameters: pain-free at 2 h, headache
relief at 2 h, cumulative pain-free, rescue medication,
second dose efﬁcacy as rescue medication, total pain-
free rate and second dose efﬁcacy to treat a recur-
rence or a relapse.
All adverse events were recorded in patient diaries
and were assessed by the investigators for intensity,
seriousness and relationship to study medication.
Laboratory parameters (haematology, glucose, creati-
nine, alkaline phosphatase, total bilirubine, ALT,
AST, gamma-GT, urea and total protein) were meas-
ured at screening and ﬁnal visits by the laboratory of
each centre.
Statistical analysis
On the basis of the results obtained in a previous
study (21), the required sample size was estimated to
be 264 patients (132 with Indoprocaf – 66 with
Indoprocaf-effervescent tablets and 66 with Indopro-
caf-coated tablets – and 132 with sumatriptan 50 mg
tablets), giving the study a power of at least 0.80 to
detect a difference of 15% in pain-free at 2 h
between patients receiving Indoprocaf and those
receiving sumatriptan, assuming a one-tailed test
with a 0.05 signiﬁcance level. Assuming that 10% of
patients did not complete the study, it was estimated
that approximately 300 patients would need to be
enrolled.
The efﬁcacy analysis was based on an ‘intention-
to-treat’ (ITT) approach that included all random-
ised patients who received at least one dose of study
medication (one effervescent tablet plus one capsule)
and had available data for the primary efﬁcacy
parameter (pain-free at 2 h) for at least one migraine
attack. Moreover, a ‘per-protocol’ (PP) sample,
including all patients who had efﬁcacy data on both
migraine attacks of moderate intensity, separated by
at least 48 h and without major violation of inclu-
sion/exclusion criteria which might impact the efﬁc-
acy of study medication, was analysed.
Pain-free, headache relief, cumulative pain-free,
associated symptoms, use and efﬁcacy of second dose
as rescue medication, total pain-free rate, recurrences,
sustained response, relapses, sustained pain-free, use
and efﬁcacy of second dose to treat a recurrence/
relapse were analysed using v
2-test for each of the
two attacks separately. In addition, the statistical
analysis including the total migraine attacks was
based on a categorial linear model for repeated meas-
ures including term for treatment, using the SAS
procedure CATMOD. Odd ratios and corresponding
two-sided 95% CI, derived from the CATMOD
procedure, were given for treatment comparisons.
The intra-individual consistency was analysed using
v
2-test.
No alpha adjustment for multiple testing was
applied because there was only a primary end-point
(the pain-free at 2 h in two migraine attacks in
total). All the other efﬁcacy variables were considered
as secondary end-points.
Missing values of severity of pain were replaced by
carrying forward the preceding value.
Differences resulting in a p-value £ 0.05 were con-
sidered to be statistically signiﬁcant. All randomised
patients who received at least one dose of study
medication (one effervescent tablet and/or one cap-
sule) and for whom safety data were available after
start of study medication were included in the safety
sample.
All data analysis was carried out according to a
pre-established analysis plan. The evaluation of the
quality and completeness of the data, identiﬁcation
of important protocol deviations and handling of
problem cases were performed regularly and ﬁnally
decided before locking and unblinding the database.
All study personnel and participants were blinded to
treatment assignment for the duration of the study.
Only the study statistician and the data manager saw
unblinded data, but none had any contact with study
participants.
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Study population
In total, 320 patients were assessed for eligibility and
297 were randomised across 14 centres in Italy. The
recruitment started on December 5, 2002 and the
trial was completed on June 15, 2004. The efﬁcacy
analyses were based on the ITT and PP samples. The
results from the ITT and the PP analysis were similar
and only the results based on the ITT sample will be
shown.
During the study period, 15 patients did not take
any study medication and were excluded from the
safety sample, which therefore consisted of 282
patients, 143 treated with Indoprocaf (72 with coated
tablets and 71 with effervescent tablets) and 139 with
sumatriptan 50 mg tablets (Figure 1). One patient
treated with sumatriptan without available diary data
was not included in the ITT sample, which therefore
consisted of 281 patients. In total, 276 migraine
attacks were treated with Indoprocaf (142 with coated
tablets and 134 with effervescent tablets) and 264 with
sumatriptan. The demographic and baseline charac-
teristics of the ITT sample were not different between
the two treatment groups (Table 1). Overall, 78% of
the patients were female and 22% were male.
The mean age ± SD was 35 ± 9.8 years. In 92% of
the patients migraine without aura was diagnosed: the
remaining patients had a diagnosis of migraine with
aura or with and without aura. During the screening
period, all the patients experienced migraine attacks:
NSAIDs, triptans, Indoprocaf and sumatriptan were
used, respectively, in 38%, 37%, 10% and 8% of cases
to treat the screening attacks. Seventy-seven per cent
of the ITT sample reported MIDAS grade III (moder-
ate disability) or IV (severe disability), without differ-
ence between Indoprocaf and sumatriptan. A higher
percentage of patients treated with Indoprocaf-coated
tablets compared with effervescent tablets reported
MIDAS grade III or IV (85% vs. 70% respectively). At
0 h, patients in the ITT sample reported headache of
moderate intensity in 47% of the attacks and severe
headache in 51%; moreover, in 72% of the attacks,
the study medication was taken within 60 min from
the onset of headache, without difference between
Indoprocaf and sumatriptan.
Of the 281 patients in the ITT sample, 41 patients
were not included in the PP sample, mostly because
only one migraine attack was treated or rescue medi-
cation had been taken within 2 h after dosing or the
headache severity at 0 h was mild. The number of
patients included in the PP sample was 240, 123
treated with Indoprocaf (63 with coated tablets
and 60 with effervescent tablets) and 117 with
sumatriptan.
Efﬁcacy
Indoprocaf vs. sumatriptan
The pain-free rates in the total attacks at 2 h postdose
were 34% with Indoprocaf and 37% with sumatriptan,
without statistically signiﬁcant differences between the
drugs (95% CI of odds-ratio: 0.57–1.28) (Table 2).
Headache relief rates in the total attacks at 2 h
postdose were 62% with Indoprocaf and 56% with
sumatriptan, without a statistically signiﬁcant differ-
ence between the two drugs (95% CI of odds-ratio:
0.82–1.84) (Table 2).
Concerning the cumulative pain-free rates, the
pain-free efﬁcacy of Indoprocaf and sumatriptan
started at 0.5 h, but became relevant (about 15% of
attacks) at 1.5 h postdose. At 3 h, about 50% of
the attacks was pain-free both with Indoprocaf and
with sumatriptan and then, the cumulative percent-
age of pain-free attacks, without use of rescue
medication, continued to increase with both the
drugs, reaching about 60–70% of pain-free attacks
at 5 h (Figure 2).
The percentage of patients reporting pain-free or
headache relief in two of two migraine attacks (intra-
individual consistency) was comparable between
Indoprocaf (17% and 42%) and sumatriptan (20%
and 42%), without statistically signiﬁcant differences
between drugs.
No statistically signiﬁcant difference was found
between Indoprocaf and sumatriptan in relieving
each of the ﬁve associated symptoms at 2 h post-
dose. At baseline (0 h), nausea, photophobia and
phonophobia were reported in 60–80%, osmophobia
in 35–40% and vomiting in about 10% of the
attacks. At 2 h postdose, the percentage of attacks
with each associated symptom was more than
halved: about 30% of nausea, photophobia and
phonophobia, 15% of osmophobia and 5% of vom-
iting (Table 3). Both Indoprocaf and sumatriptan
induced a high percentage of attacks free of any
associated symptoms at 2 h postdose (higher than
50% in both cases) (Table 3).
No statistically signiﬁcant difference was found
between Indoprocaf and sumatriptan in the percent-
age of attacks needing the second dose as rescue
medication (26% vs. 32%) (Table 4). Considering
the patients who used a second dose as rescue medi-
cation after 2 h, a higher global pain-free rate was
shown for Indoprocaf (47%) vs. sumatriptan (27%),
with a statistically signiﬁcant higher percentage of
attacks pain-free (46% vs. 23%, p < 0.05) at 2 h
postdose with Indoprocaf compared with suma-
triptan in the ﬁrst migraine attack, as well as
a higher global headache relief rate (65% with
Indoprocaf compared with 45% with sumatriptan)
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attacks headache-relieved (61% vs. 40%, p < 0.05) at
2 h postdose (Table 2).
For the secondary end-point total pain-free rate, a
statistically signiﬁcant difference (p < 0.05) was
found in favour of Indoprocaf compared with suma-
ASSESSED FOR ELIGIBILITY
(n=320)
RANDOMIZED
(n=297)
EXCLUDE (n=23)
- withdrew consent (n=15)
- not meeting inclusion criteria (n=5)
- other reasons (n=3)
INDOPROCAF (n=150) SUMATRIPTAN (n=147)
INDOPROCAF
SP (n=143)
SUMATRIPTAN
SP (n=139)
INDOPROCAF
ITT (n=143)  
SUMATRIPTAN
ITT (n=138)
INDOPROCAF
PP (n=123)
SUMATRIPTAN
PP (n=117)
EXCLUDED (n=1)
- no diary data available (n=1)
EXCLUDED (n=21)
- only one attack (n=12)
- rescue medication (n=2)
- others (n=7)
EXCLUDED (n=0)
EXCLUDED (n=20: 9 TBS, 11 EFFE)
- only one attack (n=10: 2 TBS, 8 EFFE)
- rescue medication (n=4: 3 TBS, 1 EFFE)
- others (n=6: 4 TBS, 2 EFFE)
INDOPROCAF TBS (n=75)
INDOPROCAF EFFE (n=75)
INDOPROCAF TBS
SP (n=72)
INDOPROCAF EFFE
SP (n=71)
INDOPROCAF TBS
ITT (n=72)
INDOPROCAF EFFE
ITT (n=71)
INDOPROCAF TBS
PP (n=63)
INDOPROCAF EFFE
PP (n=60)
 
EXCLUDED (n=7: 3 TBS, 4 EFFE)
- no use of study medication (n=7)
EXCLUDED (n=8)
- no use of study medication (n=8)
Figure 1 Proﬁle of subject disposition during the course of the study and inclusion in the analysis data sets: safety population (SP), intention-to-treat
sample (ITT), per-protocol sample (PP)*. *Four patients treated with Indoprocaf, three with TBS (adverse event ¼ 2 and withdrew consent ¼ 1) and
one with EFFE (adverse event), and three patients treated with sumatriptan (adverse event ¼ 1, withdrew consent ¼ 1 and lost to follow-up ¼ 1)
discontinued at any time during the study
Indoprocaf vs. sumatriptan in the acute treatment of migraine 1261
ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, August 2007, 61, 8, 1256–1269triptan in the ﬁrst (78% vs. 65%) and the total
attacks (79% vs. 69%) in the percentage of attacks
pain-free at 5 h after the ﬁrst dose of study drug
(without use of rescue medication) or 2 h after the
use of the second dose as rescue medication (Table 2;
Figure 3).
No statistically signiﬁcant difference was found
between Indoprocaf and sumatriptan in the percentage
ofrecurrenceswithin24 h (19%vs.24%), relapseswith-
in 48 h (41% vs. 34%), sustained response (49% vs.
43%)or sustainedpain-free (20%vs.24%) (Table 4).
No statistically signiﬁcant difference was found
between Indoprocaf and sumatriptan in the percentage
of attacks needing the second dose to treat a recur-
rence or a relapse (16% in both cases in total attacks)
(Table 4). The pain-free rate at 2 h after the second
dose used to treat a recurrence or a relapse was very
high with both the drugs (60% vs. 50%) (Table 2).
Table 1 Demographic and baseline characteristics of the patients (intention-to-treat sample)
Indoprocaf tbs
(n ¼ 72)
Indoprocaf effe
(n ¼ 71)
Indoprocaf total
(n ¼ 143)
Sumatriptan
(n ¼ 138)
Total
(n ¼ 281)
Sex (n, %)
Male 10 (14) 20 (28) 30 (21) 31 (22) 61 (22)
Female 62 (86) 51 (72) 113 (79) 107 (78) 220 (78)
Age (years)
Mean 35 34 34 36 35
Range 20–60 19–58 19–60 18–64 18–64
Migraine diagnosis (n, %)
Migraine without aura 67 (93) 64 (90) 131 (92) 129 (93) 260 (92)
Migraine with aura 1 (1) 5 (7) 6 (4) 4 (3) 10 (4)
Migraine with and without aura 4 (6) 2 (3) 6 (4) 5 (4) 11 (4)
MIDAS grade (n, %)
I 3 (4) 11 (16) 14 (10) 14 (10) 28 (10)
II 8 (11) 10 (14) 18 (13) 18 (13) 36 (13)
III 25 (35) 23 (32) 48 (33) 48 (35) 96 (34)
IV 36 (50) 27 (38) 63 (44) 58 (42) 121 (43)
Indoprocaf indicates indomethacin, prochlorperazine and caffeine; tbs, coated tablets; effe, effervescent tablets.
Table 2 Pain-free and headache relief with ﬁrst dose, pain-free and headache relief with second dose as rescue
medication, pain-free and headache relief with second dose to treat a recurrence/relapse (at 2 h postdose) and total
pain-free rate with Indoprocaf and sumatriptan (intention-to-treat sample)*
First attack Second attack Total attacks
Indoprocaf Sumatriptan Indoprocaf Sumatriptan Indoprocaf Sumatriptan
Pain-free (ﬁrst dose) 45/143 (32) 49/138 (36) 48/133 (36) 49/126 (39) 93/276 (34) 98/264 (37)
Headache relief (ﬁrst dose) 82/143 (57) 79/138 (57) 88/133 (66) 70/126 (56) 170/276 (62) 149/264 (56)
Pain-free (second dose
as rescue medication)
21/46 (46) 10/43 (23) 12/25 (48) 13/42 (31) 33/71 (47) 23/85 (27)
Headache relief (second dose
as rescue medication)
28/46 (61) 17/43 (40) 18/25 (72) 21/42 (50) 46/71 (65) 38/85 (45)
Pain-free (second dose
to treat a recurrence/relapse)
13/26 (50) 11/23 (48) 14/19 (74) 10/19 (53) 27/45 (60) 21/42 (50)
Headache relief (second dose
to treat a recurrence/relapse)
19/26 (73) 19/23 (83) 16/19 (84) 16/19 (84) 35/45 (78) 35/42 (83)
Total pain-free rate 112/143 (78) 90/138 (65) 105/133 (79) 92/126 (73) 217/276 (79) 182/264 (69)
*Values are number of attacks complying with the parameter/total no. of attacks (percentage). Indoprocaf indicates indomethacin,
prochlorperazine and caffeine. p < 0.05 vs. sumatriptan (v
2-test). Total pain-free rate is the total percentage of attacks pain-free at
5 h without use of rescue medication and 2 h after the second dose of study drug as rescue medication.
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attacks with Indoprocaf or sumatriptan, a higher per-
centage of pain-free attacks was reported with Indo-
procaf than with sumatriptan (76% vs. 66% of
attacks with pain-free at 2 h or pain-free at 5 h or
pain-free with second dose as rescue medication or
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Figure 2 Cumulative pain-free rates without use of rescue medication in the total attacks (A) with Indoprocaf or
sumatriptan and (B) with Indoprocaf-coated tablets (tbs) or Indoprocaf-effervescent tablets (effe) (intention-to-treat sample)
Table 3 Attacks with associated symptoms at baseline and 2 h postdose and attacks free of any associated symptoms at
2 h postdose (intention-to-treat sample)*
First attack Second attack Total attacks
Indoprocaf
(n ¼ 143)
Sumatriptan
(n ¼ 138)
Indoprocaf
(n ¼ 133)
Sumatriptan
(n ¼ 126)
Indoprocaf
(n ¼ 276)
Sumatriptan
(n ¼ 264)
Nausea
Baseline 86 (60) 79 (57) 75 (56) 80 (64) 161 (58) 159 (60)
2 h 47 (33) 35 (25) 32 (24) 31 (25) 79 (29) 66 (25)
Vomiting
Baseline 12 (8) 15 (11) 17 (13) 16 (13) 29 (11) 31 (12)
2 h 4 (3) 7 (5) 8 (6) 6 (5) 12 (4) 13 (5)
Photophobia
Baseline 100 (70) 108 (78) 91 (68) 92 (73) 191 (69) 200 (76)
2 h 46 (32) 49 (36) 38 (29) 42 (33) 84 (30) 91 (35)
Phonophobia
Baseline 94 (66) 104 (75) 91 (68) 94 (75) 185 (67) 198 (75)
2 h 44 (31) 45 (33) 38 (29) 36 (29) 82 (30) 81 (31)
Osmophobia
Baseline 54 (38) 46 (33) 53 (40) 48 (38) 107 (39) 94 (36)
2 h 23 (16) 22 (16) 20 (15) 18 (14) 43 (16) 40 (15)
Attacks free of associated symptoms
2 h 70 (49) 72 (52) 73 (55) 68 (54) 143 (52) 140 (53)
*Values are number (percentage) of attacks. Indoprocaf indicates indomethacin, prochlorperazine and caffeine.
Indoprocaf vs. sumatriptan in the acute treatment of migraine 1263
ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, August 2007, 61, 8, 1256–1269pain-free with second dose to treat a relapse)
(Figure 4).
Indoprocaf-coated tablets vs. Indoprocaf-
effervescent tablets
A statistically signiﬁcant difference was found in
favour of Indoprocaf-effervescent tablets in the pain-
free rate (41% vs. 22%) and in the headache relief
rate (66% vs. 49%) at 2 h postdose in the ﬁrst attack
(Table 5; Figure 5). The cumulative pain-free rates of
Indoprocaf-coated tablets were lower than those of
Indoprocaf-effervescent tablets at all the times, and
lower to those of sumatriptan within 2 h, but similar
within 3 and 5 h postdose (Figure 2). No statistically
signiﬁcant differences between Indoprocaf-efferves-
cent and coated tablets were found in the efﬁcacy of
the re-dosing (Table 5). A statistically signiﬁcant dif-
ference (p < 0.05) in favour of the effervescent tab-
lets was found in the total pain-free rate in the total
attacks (84% vs. 73%) (Table 5 and Figure 5). The
total pain-free rate of Indoprocaf-coated tablets was
lower than that of effervescent tablets, but higher
than that of sumatriptan (Table 5).
Safety
Indoprocaf and sumatriptan were regarded as safe
and well-tolerated treatments for the acute attacks of
migraine. A total of 31 patients (22%) in the Indo-
procaf group and 25 patients (18%) in the sumatrip-
tan group reported at least one treatment-emergent
adverse event (Table 6). Twenty-three patients trea-
ted with Indoprocaf (16%) and 14 patients treated
with sumatriptan (10%) reported at least one related
treatment-emergent adverse event. No serious
adverse events were reported with Indoprocaf, while
only one serious adverse event (severe headache) was
reported with sumatriptan. Three patients in the
Indoprocaf group (one for malaise, one for malaise
and loss of consciousness and one for vertigo) and
one patient in the sumatriptan group (for headache)
dropped out because of adverse events (Table 6). A
similar number of treatment-emergent adverse events
was found after one (36 events) or two doses (39
events) of Indoprocaf; on the contrary, the number
of treatment-emergent adverse events was three times
higher with two doses (31 events) of sumatriptan in
comparison to one dose (nine events). The most fre-
quent non-serious related adverse events were repor-
ted in the nervous system or gastrointestinal system
with both the drugs, with vertigo (4.9% of safety
sample) for Indoprocaf and somnolence (2.2% of
safety sample) for sumatriptan as the most com-
monly reported events. No differences were detected
in the safety proﬁle between Indoprocaf-coated tab-
lets and -effervescent tablets. There was no clinically
Table 4 Recurrences, sustained response, relapses, sustained pain-free and use of second dose (intention-to-treat
sample)*
First attack Second attack Total attacks
Indoprocaf Sumatriptan Indoprocaf Sumatriptan Indoprocaf Sumatriptan
Recurrences (24 h) 16/82 (20) 19/79 (24) 16/88 (18) 16/70 (23) 32/170 (19) 35/149 (24)
Sustained response 64/143 (45) 60/138 (44) 72/133 (54) 54/126 (43) 136/276 (49) 114/264 (43)
Relapses (48 h) 22/45 (49) 20/49 (41) 16/48 (33) 13/49 (27) 38/93 (41) 33/98 (34)
Sustained pain-free 23/143 (16) 29/138 (21) 32/133 (24) 35/126 (28) 55/276 (20) 64/264 (24)
Use of second dose as
rescue medication (2–48 h)
46/143 (32) 43/138 (31) 25/133 (19) 42/126 (33) 71/276 (26) 85/264 (32)
Use of second dose
to treat a recurrence/relapse
26/143 (18) 23/138 (17) 19/133 (14) 19/126 (15) 45/276 (16) 42/264 (16)
*Values are number of attacks complying with the parameter/total no. of attacks (percentage). Indoprocaf indicates indomethacin,
prochlorperazine and caffeine.
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Figure 4 Summary of results obtained treating the total attacks with Indoprocaf (n ¼ 276 attacks) or sumatriptan
(n ¼ 264 attacks) (intention-to-treat sample)
Table 5 Pain-free and headache relief with ﬁrst dose, pain-free and headache relief with second dose as rescue
medication, pain-free and headache relief with second dose to treat a recurrence/relapse (at 2 h postdose) and total
pain-free rate with Indoprocaf-coated tablets and -effervescent tablets (intention-to-treat sample)*
First attack Second attack Total attacks
Indoprocaf
tbs
Indoprocaf
effe
Indoprocaf
tbs
Indoprocaf
effe
Indoprocaf
tbs
Indoprocaf
effe
Pain-free (ﬁrst dose) 16/72 (22) 29/71 (41) 23/70 (33) 25/63 (40) 39/142 (28) 54/134 (40)
Headache relief (ﬁrst dose) 35/72 (49) 47/71 (66) 45/70 (64) 43/63 (68) 80/142 (56) 90/134 (67)
Pain-free (second dose
as rescue medication)
11/27 (41) 10/19 (53) 6/16 (38) 6/9 (67) 17/43 (40) 16/28 (57)
Headache relief (second dose
as rescue medication)
14/27 (52) 14/19 (74) 10/16 (63) 8/9 (89) 24/43 (56) 22/28 (79)
Pain-free (second dose
to treat a recurrence/relapse)
4/8 (50) 9/18 (50) 8/9 (89) 6/10 (60) 12/17 (71) 15/28 (54)
Headache relief (second dose
to treat a recurrence/relapse)
7/8 (88) 12/18 (67) 9/9 (100) 7/10 (70) 16/17 (94) 19/28 (68)
Total pain-free rate 52/72 (72) 60/71 (85) 52/70 (74) 53/63 (84) 104/142 (73) 113/134 (84)
*Values are number of attacks complying with the parameter/total no. of attacks (percentage). Indoprocaf indicates indomethacin,
prochlorperazine and caffeine; tbs indicates coated tablets; effe indicates effervescent tablets. p < 0.05 vs. Indoprocaf tbs. Total
pain-free rate is the total percentage of attacks pain-free at 5 h without use of rescue medication and 2 h after the second dose of
study drug as rescue medication.
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pressure values from baseline to the ﬁnal study
assessment.
Discussion
The aim of this double-blind, double-dummy, rand-
omised, parallel group, multicentre study was to com-
pare the efﬁcacy and safety of Indoprocaf tablets with
sumatriptan 50 mg tablets in the acute treatment of
migraine. As subanalysis, a comparison between Indo-
procaf-coated and -effervescent tablets on the most
important efﬁcacy parameters was also performed.
In this study patients with migraine with or with-
out aura according to the IHS criteria (25) were
enrolled. The patient population analysed had a
more severe baseline intensity of migraine (47% of
moderate and 51% of severe migraine) compared to
that commonly included in triptan studies (65% of
moderate and 35% of severe migraine) (28,29) and
77% of patients reported a baseline moderate or
severe disability (MIDAS grade III and IV) (27).
Differently from the most part of the studies with
triptans, where headache relief was used as primary
efﬁcacy end-point (23), and according to the most
recent guidelines (24,26), in this study pain-free at
2 h postdose was used as primary efﬁcacy end-point.
Moreover, all the secondary efﬁcacy parameters were
analysed according to these recent international
guidelines (24,26).
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Figure 5 (A) Percentage of attacks pain-free at 2 h postdose with Indoprocaf-coated tablets (tbs) or Indoprocaf-
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Table 6 Summary of adverse events (safety sample)*
Indoprocaf (n ¼ 143) Sumatriptan (n ¼ 139)
Patients reporting at least one TEAE (n, %) 31 (22) 25 (18)
Patients reporting at least one related TEAE (n, %) 23 (16) 14 (10)
Serious adverse events (n) – 1
Patients dropped-out as a result of adverse events (n) 3 1
*Indoprocaf indicates indomethacin, prochlorperazine and caffeine; TEAE indicates treatment-emergent adverse events.
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two migraine attacks treated with the same drug, dif-
ferently from the most part of the studies with trip-
tans, where only one attack was studied (23). A
repeated intake of the study medication for multiple
attacks is recommended, because it is expected to
increase the discriminative power of a trial if outcome
is averaged across multiple attacks for each patient
and it is used to evaluate consistency of response (24).
In this study, it was chosen to compare the lowest
effective oral doses of Indoprocaf and sumatriptan
for the initial dosing. However, it was given the pos-
sibility to take a second dose as rescue medication
after 2 h or to treat a recurrence/relapse within 48 h,
to evaluate the efﬁcacy of re-dosing of the drugs in
the same attack.
Regarding the primary efﬁcacy parameter, there
was no statistically signiﬁcant difference between In-
doprocaf and sumatriptan in the percentage of pain-
free attacks (respectively, 34% and 37% of total
attacks). This pain-free rate at 2 h conﬁrms the
widely published mean absolute pain-free response of
30% with oral sumatriptan (23). Therefore, the
encapsulation of sumatriptan did not inﬂuence the
efﬁcacy of the drug, as evidenced also in a recently
published meta-analysis comparing the time-course
of response up to 4 h of encapsulated and commer-
cial sumatriptan (30).
No signiﬁcant differences were found for headache
relief between Indoprocaf and sumatriptan (62% vs.
56% respectively). Headache relief response rates of
about 60% are commonly reported with the triptans
(23).
Analysing the cumulative percentage of attacks
becoming pain-free without use of rescue medica-
tion, it was observed that the pain-free response of
both the drugs started at 30 min, but became rele-
vant (more than 15%) starting from 1.5 h postdose.
At 3 h, 50% of the attacks was pain-free both with
Indoprocaf and with sumatriptan and then, the
cumulative percentage of pain-free attacks, without
use of rescue medication, continued to increase with
both the drugs, reaching 60–70% of pain-free attacks
at 5 h postdose.
The percentage of attacks with each associated
symptom at baseline was similar in all the treatment
groups and conﬁrms those reported in literature
(60–70% of nausea, photophobia and phonophobia;
10–20% of vomiting and 30–40% of osmophobia)
(28). Both drugs showed a similar efﬁcacy in reliev-
ing the associated symptoms: at 2 h postdose, the
percentage of attacks with each associated symptom
was more than halved and more than 50% of the
attacks were free of any associated symptoms.
No statistical difference was found between Indo-
procaf and sumatriptan in the percentage of attacks
with use of the second dose of study drug as rescue
medication, about 30%, that is similar to the per-
centage reported in the literature with the triptans
(28).
For both drugs the average percentages of recur-
rences (22%) or relapses (38%) and of sustained
response (46%) or sustained pain-free (22%)
obtained in this study conﬁrm those reported in the
literature with the triptans (23).
The pain-free rate of oral Indoprocaf (34%) was
lower than that obtained in an open, cross-over trial
(21) with rectal Indoprocaf (49%) vs. rectal suma-
triptan (34%). Rectal Indoprocaf has almost the
same quantitative composition of the oral tablets
(both the formulations contain indomethacin 25 mg
and caffeine 75 mg; prochlorperazine 2 mg and 4 mg
are contained, respectively, in the rectal and in the
oral formulation); rectal sumatriptan contains 25 mg
of active ingredient, that is the halved dosage of the
oral dose used in this study. Comparing the results
of these studies, it could be suggested that for the
oral administration the double quantitative of active
ingredients is required compared to the rectal one,
probably because of the well known delayed absorp-
tion during migraine attacks (23). Therefore, consid-
ering the very low dosage of Indoprocaf used in this
study, the results obtained are particularly valuable
(especially with the effervescent tablets). Moreover,
the rectal formulations of both Indoprocaf and sum-
atriptan showed to induce a lower percentage of
relapse (respectively, 8% and 12%) than the oral
forms (41% and 34%) (21).
The second dose of study medication, taken as res-
cue medication when the severity of headache was
still at a score of 2 or 3 at 2 h after dosing, showed
to be very effective, especially with Indoprocaf with a
statistically signiﬁcant difference compared with
sumatriptan in the ﬁrst attack (46% vs. 23% of pain-
free attacks and 61% vs. 40% of headache-relieved
attacks after 2 h).
Considering the total percentage of attacks pain-
free at 5 h with the initial dose of study drug (with-
out use of rescue medication) or at 2 h after the
second dose of study drug, a statistically signiﬁcant
difference was obtained in favour of Indoprocaf
compared with sumatriptan (79% vs. 69%). This dif-
ference is mainly because of the higher pain-free
efﬁcacy both of the ﬁrst dose of Indoprocaf from
3 to 5 h and of the second dose compared with
sumatriptan.
It has to be considered that to our knowledge this
is the ﬁrst study where the effect of a second dose of
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treatment of migraine attacks was investigated.
The efﬁcacy of the second dose of study medica-
tion was conﬁrmed when the second dose was taken
to treat a recurrence or a relapse, that is when the
headache relieved at 2 h and the headache returned
within 48 h of initial dosing with an average high
pain-free rate (55%).
Considering the total number of attacks treated
with the study drugs, only 24% of attacks with Indo-
procaf and 34% with sumatriptan were not treated
effectively in the 48 h of observation time.
Moreover, a higher pain-free rate at 2 h was found
for Indoprocaf-effervescent tablets, with a statistical
difference vs. Indoprocaf-coated tablets only in the
ﬁrst attack (41% vs. 22%). A statistical difference
between the two formulations was found also in the
total pain-free rate, because also the second dose of
Indoprocaf-effervescent tablets as rescue medication
was more effective than that of coated tablets. The
possible reasons for this difference between Indopro-
caf-effervescent and -coated tablets could be a
delayed oral absorption of coated tablets in patients
with migraine attacks, the encapsulation of coated
tablets or the fact that a higher percentage of patients
treated with the coated tablets compared with effer-
vescent tablets reported MIDAS grade III or IV (85%
vs. 70% respectively). However, although Indopro-
caf-coated tablets were less effective than the efferves-
cent tablets, they were at least as effective as
sumatriptan for the majority of the secondary end-
points.
Indoprocaf and sumatriptan showed a similar
safety proﬁle, with a percentage of patients reporting
at least one treatment emergent adverse event, which
was similar or lower to that reported in the literature
with sumatriptan 50 mg (28,31). In the open, cross-
over trial comparing the rectal formulations of Indo-
procaf and sumatriptan, both the drugs were partic-
ularly well tolerated with only 9% of patients
reporting at least one adverse event (21).
This study, conducted according to the most
recent guidelines (24,26), demonstrated that the
efﬁcacy of the initial dosing of Indoprocaf was not
higher than that of sumatriptan, but that the strategy
to use the lowest effective dose as soon as the head-
ache occurred, followed by a second dose if the
headache has not relieved or to treat a relapse, was
very effective, especially with Indoprocaf.
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